Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of AZD5718 in Proteinuric Chronic Kidney Disease
2020-002263-54Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atuliflapon in chronic kidney disease (CKD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in log-transformed urine albumin-to-creatinine ratio (UACR) from baseline to Week 20. Started Sep 2020; status: terminated.
02
Drugs
atuliflapon
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-002263-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002263-54.